Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 457-690-5 | CAS number: 23432-65-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
RDT oral (OECD 407): NOAEL = 150 mg/kg bw/day (males/females)
RDT inhalation: no data available
RDT dermal: no data available
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 25 Sep - 30 Oct 2003
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- (1995)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayrisches Landesamt für Arbeitsschutz, Arbeitsmedizin und Sicherheitstechnik
- Limit test:
- no
- Species:
- rat
- Strain:
- other: Hsd: Wistar rats (HsdBrl:WH, Full-Barrier)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Winkelmann GmbH, Borchen, Germany
- Age at study initiation: 7 – 9 weeks
- Weight at study initiation: 130 – 151 g (females), 163 – 186 g (males)
- Housing: Animals were caged in macrolon cages on Altromin saw fiber bedding.
- Diet: Altromin 1324 maintenance diet for rats and mice, ad libitum
- Water: (tap/filtered) water, ad libitum
- Acclimation period: adequate period
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3
- Humidity (%): 55 ± 10
- Air changes (per hr): 10
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- VEHICLE
- Amount of vehicle (if gavage): 5 mL/kg bw
- Justification for choice of vehicle: The vehicle was chosen due to its non-toxic characteristics and the chemical properties of the test item.
- Lot/batch no.: 062K0006
MAXIMUM DOSE VOLUME APPLIED: 5 mL/kg bw
DOSAGE PREPARATION: The test substance was suspended in corn oil. The homogeneity of the preparations was visually checked. During the application procedure no obvious separation was checked. - Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- Not applicable
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily, 7 days/week
- Dose / conc.:
- 150 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on a previous dose range finding study
- Positive control:
- Not required
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once a day for general health condition and at least twice a day for mortality and morbidity
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once before the first exposure and in the final week
BODY WEIGHT: Yes
- Time schedule for examinations: Days 0, 7, 14, 21, 27
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each group determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
HAEMATOLOGY: Yes
- Time schedule for collection of blood: during necropsy
- Anaesthetic used for blood collection: Yes
- Animals fasted: Yes
- How many animals: all animals (20)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: during necropsy
- Animals fasted: Yes
- How many animals: all animals (20)
URINALYSIS: Yes
- Time schedule for collection of urine: during necropsy
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: once before the first exposure and in the final week
- Dose groups that were examined: all
- Battery of functions tested: Standard functional observational battery according to Moser et al (1991): sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, all animals
ORGAN WEIGHTS: Yes, all animals (liver, kidneys, adrenals, testes, epididymides, thymus, spleen, brain, heart)
HISTOPATHOLOGY: Yes, all animals of control and high dose groups (all gross lesions, brain (representative regions including cerebrum, cerebellum and pons), spinal cord, liver, kidneys, adrenals, stomach, small and large intestines (including Peyer's patches, lymphnodes acc. to application), thymus, thyroid, spleen, lung and trachea, heart, gonades, acc. sex organs (e.g. uterus, prostate, vesicula seminalis), urinary bladder, lymph nodes (lymphocentrum mandibulare; Lnn. axillares), peripheral nerve, bone marrow) - Statistics:
- For statistical analysis one-way analysis of variance (ANOVA) was carried out, followed by Student's t-test to reveal any differences between control and test groups. For parameters indicating no compound-related alterations and/or showing a high degree of variation (both in control and test groups) no statistical evaluation was carried out.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- 500 mg/kg bw/day: Hypoproteinaemia (males/females), reduced cholesterol (males);
1000 mg/kg bw/day: Hypoproteinaemia (males), reduced cholesterol (males) - Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- 150 mg/kg bw/day: decreased rel. thymus weight (males, non-adverse)
500 mg/kg bw/day: decreased rel./abs. adrenals/thymus weight (males/females, adverse);
1000 mg/kg bw/day: decreased rel./abs. adrenals (males, adverse)/thymus weight (males/females, adverse) - Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- 1000 mg/kg bw/day: splenic peritonitis and thymic atrophy (males/females), testicular tubular degeneration and epididymal hypospermia (males)
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITY
There were no mortality and no severe clinical signs observed throughout the study period.
BODY WEIGHT AND WEIGHT GAIN
Body weight development was unaffected by treatment.
FOOD CONSUMPTION
Food consumption was unaffected by treatment.
HAEMATOLOGY
There were no effects of toxicological relevance noted on haematology parameters such as haemoglobin (Hb), haematocrit (Hct), erythrocyte count (RBC), blood clotting and different leucocyte count.
Significant decrease of total leucocyte count (WBC) was noted for medium dose males (500 mg/kg bw/day); however, the biological relevance is equivocal as no other findings were observed confirming disturbance in the white blood cell system. Significantly decreased platelet counts were noted for high dose (1000 mg/kg bw/day) males and females (68.9 and 71.6% as compared to the control group) and medium dose (500 mg/kg bw/day) males (65.6% as compared to the control group), respectively. However, toxicological relevance was considered equivocal, especially as high values were also observed in the male control group.
CLINICAL CHEMISTRY
There were no effects of toxicological relevance noted on clinical chemistry parameters such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), glucose (GLU), urea, creatinine (CREA), albumin (ALB), natrium and kalium. Two dosed male groups (medium and high dose) showed significant reduced CHOL-values. Toxicological relevance of this finding is equivocal. Compound relation and dose dependency may be assumed although all values are within the expected range. Significant differences in total protein are found for the male medium and high dose and female medium dose, but not for the female high dose. Hypoproteinaemia is normally observed with chronic hepatic disturbance, nephrotic disturbance or reduced protein synthesis, e.g. due to malassimilation. As the mean values of both, female and male high dose groups, are less than the expected range compound relation and dose dependency may be assumed.
URINALYSIS
There were no effects of toxicological relevance noted on any of the tested urinalysis parameters.
NEUROBEHAVIOUR
There were no effects noted concerning functional and behavioural examination.
ORGAN WEIGHTS
The mean absolute and relative adrenals weight in the male medium and high dose (500, 1000 mg/kg bw/day) groups, as well as the mean absolute adrenals weight in the female medium dose group was slightly lower than the adrenals weight in the corresponding control groups, reaching statistical significance (p<0.05). This finding is assumed to be compound related, indicating a possible disturbance in the endocrine system.
The mean absolute and relative thymus weight in the male and female medium and high dose groups, as well as the mean relative thymus weight in the male low dose (150 mg/kg bw/day) group was reduced compared to the thymus weight in the corresponding control groups, reaching statistical significance (p<0.05). This finding is assumed to be compound related for the medium and high dose group and was confirmed by the histopathological findings for the high dose groups. Beside the physiological atrophy in older animals, reduction of thymus weight (thymic atrophy) is normally observed with disturbance of the immunological system.
The mean absolute and relative testes weight in the male high dose (1000 mg/kg bw/day) was lower than the testes weight in the control group, reaching statistical significance (p<0.05). This finding is assumed to be compound related, and was confirmed by the histopathological assessment.
The mean absolute and relative epididymides weight in the male high dose (1000 mg/kg bw/day) was lower than the epididymides weight in the control group, reaching statistical significance (p<0.05). This finding is assumed to be compound related, and was confirmed by the histopathological assessment.
GROSS PATHOLOGY
Disseminated white depositions on the spleen surface were observed of two males of the medium dose group (500 mg/kg bw/day), of three females and all males of the high dose group (1000 mg/kg bw/day).
HISTOPATHOLOGY: NON-NEOPLASTIC
There were treatment-related lesions in the spleen and thymus of both sexes and the thyroids, epididymides and testes of male rats. Significant incidences of splenic peritonitis and thymic atrophy were limited to the high dose group (1000 mg/kg bw/day). Treatment-related lesions of follicular cell hypertrophy were present in the thyroids of male rats of the high dose group. Testicular tubular degeneration and epididymal hypospermia and degenerate sperm forms (all at a minimal or mild level) were only present in high dose group males. The treatment-related findings were of a minor degree in each organ. There were insignificant incidences of splenic focal fibrous peritonitis, thymic atrophy and thyroid follicular cell hypertrophy in the medium dose group (500 mg/kg bw/day). The histopathological “no-effect” level of treatment with the test material over a period of 28 days was established to be 500 mg/kg. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 150 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Overall effects: organ weights; adrenals, thymus, testes and epididymides histopathology; lesions in the spleen, thymus, thyroid, testes and epididymides clinical chemistry; hypoproteinaemia
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 500 mg/kg bw/day (actual dose received)
- System:
- immune system
- Organ:
- spleen
- thymus
- thyroid gland
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- System:
- male reproductive system
- Organ:
- cauda epididymis
- testes
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- System:
- endocrine system
- Organ:
- adrenal glands
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Conclusions:
- The test item was examined for toxicity after repeated exposure in a subacute study with rats according to OECD 407 and in compliance with GLP. Based on the treatment related findings and effects of toxicological relevance the NOAEL is therefore 150 mg/kg bw/day.
Reference
Table 1: Procentual mean TP values
Procentual Mean Biochemistry Value |
TP |
|
||
|
|
|
|
|
Group |
Sex |
Mean |
|
% |
|
|
g/L |
|
|
|
|
|
|
|
C |
m |
56.82 |
|
100 |
C |
f |
55.80 |
|
100 |
|
|
|
|
|
LD |
m |
56.66 |
|
99.72 |
LD |
f |
56.02 |
|
100.39 |
|
|
|
|
|
MD |
m |
53.02 |
* |
93.31 |
MD |
f |
51.80 |
* |
92.83 |
|
|
|
|
|
HD |
m |
50.18 |
* |
88.31 |
HD |
f |
50.96 |
|
91.33 |
* significant (p<0.05); as determinded with the individual values
C: control
LD: low dose
MD: medium dose
HD: high dose
TP: total protein
m: male
f: female
Table 2: Procentual mean absolute and relative organ weight adrenals, thymus, testes and epididymides
Procentual mean absolute and relative organ weight
|
|||||||
|
|
|
|
|
|
|
|
Adrenals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group |
Sex |
Absolute |
|
Relative |
|
% absolute |
% relative |
|
|
mean in g |
|
mean in % |
|
|
|
|
|
|
|
|
|
|
|
C |
m |
0.051 |
|
0.018 |
|
100.00 |
100.00 |
C |
f |
0.061 |
|
0.035 |
|
100.00 |
100.00 |
|
|
|
|
|
|
|
|
LD |
m |
0.046 |
|
0.017 |
|
90.20 |
94.44 |
LD |
f |
0.056 |
|
0.032 |
|
91.80 |
91.43 |
|
|
|
|
|
|
|
|
MD |
m |
0.037 |
* |
0.013 |
* |
72.55 |
72.22 |
MD |
f |
0.045 |
* |
0.025 |
|
73.77 |
71.43 |
|
|
|
|
|
|
|
|
HD |
m |
0.037 |
* |
0.013 |
* |
72.55 |
72.22 |
HD |
f |
0.053 |
|
0.031 |
|
86.89 |
88.57 |
|
|
|
|
|
|
|
|
Thymus |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group |
Sex |
Absolute |
|
Relative |
|
% absolute |
% relative |
|
|
mean in g |
|
mean in % |
|
|
|
|
|
|
|
|
|
|
|
C |
m |
0.63 |
|
0.21 |
|
100.00 |
100.00 |
C |
f |
0.44 |
|
0.24 |
|
100.00 |
100.00 |
|
|
|
|
|
|
|
|
LD |
m |
0.46 |
|
0.17 |
* |
72.61 |
80.28 |
LD |
f |
0.36 |
|
0.20 |
|
82.27 |
84.45 |
|
|
|
|
|
|
|
|
MD |
m |
0.35 |
* |
0.12 |
* |
56.05 |
57.28 |
MD |
f |
0.25 |
* |
0.14 |
* |
57.73 |
59.66 |
|
|
|
|
|
|
|
|
HD |
m |
0.26 |
* |
0.09 |
* |
40.61 |
42.72 |
HD |
f |
0.19 |
* |
0.11 |
* |
43.41 |
47.48 |
|
|
|
|
|
|
|
|
Testes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group |
Sex |
Absolute |
|
Relative |
|
% absolute |
% relative |
|
|
mean in g |
|
mean in % |
|
|
|
|
|
|
|
|
|
|
|
C |
m |
3.08 |
|
1.06 |
|
100.00 |
100.00 |
|
|
|
|
|
|
|
|
LD |
m |
3.01 |
|
1.14 |
|
97.57 |
107.65 |
|
|
|
|
|
|
|
|
MD |
m |
3.13 |
|
1.08 |
|
101.52 |
102.27 |
|
|
|
|
|
|
|
|
HD |
m |
1.78 |
* |
0.64 |
* |
57.56 |
60.53 |
|
|
|
|
|
|
|
|
Epididymides |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Group |
Sex |
Absolute |
|
Relative |
|
% absolute |
% relative |
|
|
mean in g |
|
mean in % |
|
|
|
|
|
|
|
|
|
|
|
C |
m |
0.98 |
|
0.34 |
|
100.00 |
100.00 |
|
|
|
|
|
|
|
|
LD |
m |
0.97 |
|
0.37 |
|
98.57 |
108.58 |
|
|
|
|
|
|
|
|
MD |
m |
0.92 |
|
0.32 |
|
93.99 |
94.38 |
|
|
|
|
|
|
|
|
HD |
m |
0.74 |
* |
0.27 |
* |
75.46 |
78.70 |
* significant (p<0.05); as determinded with the individual values
C: control
LD: low dose
MD: medium dose
HD: high dose
m: male
f: female
For further information on histopathological results refer to "Remarks on results including tables and figures"
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 150 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The available information comprises an adequate and reliable study, and is thus sufficient to fulfil the standard information requirements set out in Annex VIII, 8.6, of Regulation (EC) No 1907/2006.
- System:
- immune system
- Organ:
- spleen
- thymus
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Repeated dose toxicity: oral route
A key repeated dose toxicity (28-day, oral) study with methyl-N-{[dimethoxy(methyl)silyl]methyl}carbamate (CAS 23432-65-7) is available and was performed according to OECD TG 407 and in compliance with GLP (BSL, 2004). In this subacute toxicity study groups of five Wistar rats of each sex per dose were administered doses of 150, 500 or 1000 mg/kg bw/day or vehicle alone (corn oil) once daily for 28 consecutive days via oral gavage. Dose selection of the test material was based on a previous 14-day range finding study (BSL, 2003). Animals were observed for mortalities and clinical signs at least once a day, and detailed clinical observations were performed in the final week. Body weights, food consumption and neurobehavioural examination were recorded. Haematology parameters such as Hb, Hct, RBC, blood clotting and different leucocyte counts were evaluated. Clinical chemistry included aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, glucose, urea, creatinine, albumin, Na and K.
No mortality and no severe clinical signs of toxicity were observed throughout the study period. Food consumption and body weight development were unaffected by treatment. Hematology, urinalysis and neurobehavioural examinations revealed no effects of toxicological relevance. Clinical chemistry revealed significant differences in total protein are found for males at doses of 500 and 1000 mg/kg bw/day and females at a dose of 500 mg/kg bw/day. Hypoproteinaemia is normally observed with chronic hepatic disturbance, nephrotic disturbance or reduced protein synthesis, e.g. due to malassimilation. As the mean values of both, female and male high dose groups are less than the expected range in control animals, compound relation and dose dependency may be assumed.
The mean absolute and relative adrenals weight in the male 500 and 1000 mg/kg bw/day dose groups, as well as the mean absolute adrenals weight in the female 500 mg/kg bw/day dose group were slightly lower than the adrenals weight in the corresponding control groups, reaching statistical significance (p<0.05). This finding is assumed to be compound related, indicating a possible disturbance in the endocrine system. The mean absolute and relative thymus weight in the male and female 500 and 1000 mg/kg bw/day dose groups, as well as the mean relative thymus weight in the male 150 mg/kg bw/day dose group were reduced compared to the thymus weight in the corresponding control groups, reaching statistical significance (p<0.05). This finding is assumed to be compound related for the 500 and 1000 mg/kg bw/day dose group and was confirmed by the histopathological findings for the high dose groups. The mean absolute and relative testes and epididymides weight in the male 1000 mg/kg bw/day dose group was lower than in the control group, reaching statistical significance (p<0.05). This finding is assumed to be compound related, and was confirmed by the histopathological assessment.
Histopathology (non-neoplastic) revealed treatment-related lesions in the spleen and thymus of both sexes as well as the thyroids, epididymides and testes of male rats. Significant incidences of splenic peritonitis and thymic atrophy were limited to the 1000 mg/kg bw/day dose group. Treatment-related lesions of follicular cell hypertrophy were present in the thyroids of male rats of the 1000 mg/kg bw/day dose group. Testicular tubular degeneration and epididymal hypospermia and degenerate sperm forms (all at a minimal or mild level) were only present at the highest dosage level. The treatment-related findings were of a minor degree in each organ. There were insignificant incidences of splenic focal fibrous peritonitis, thymic atrophy and thyroid follicular cell hypertrophy in the 500 mg/kg bw/day dose group.
The
decreased organ weights of the adrenals and thymus as well as
histopathological evaluated lesions in the spleen, thymus, thyroid,
testes and epididymides are considered treatment related findings and
effects of toxicological relevance. Therefore, the NOAEL and LOAEL for
males/females are considered to be 150 mg/kg bw/day and 500 mg/kg
bw/day, respectively.
Justification for classification or non-classification
The available data on repeated dose toxicity of the registered substance do not meet the criteria for classification according to Regulation (EC) No 1272/2008, and are therefore conclusive but nor sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.